Yuan Cheng, Xu Xin-Hua, Xu Lu, Sun Min, Ni Li-Hua, Liu Yang, Ran Feng, Wang Xiao-Long, Chen Zhuo, Zhang Kun, Zeng Guang
The First College of Clinical Medical Science, China Three Gorges University Department of Oncology, Yichang Central People's Hospital, Yichang Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, Wuhan, China Zhongda Hospital, Southeast University, Nanjing Central Hospital of Enshi Autonomous Prefecture, Enshi, China Klinikum rechts der Isar Technical University of Munich, München, Germany Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA.
Medicine (Baltimore). 2017 Jun;96(24):e7153. doi: 10.1097/MD.0000000000007153.
Developing a new reliable prognostic marker to predict the prognosis and supply better and more suitable therapy for patients with nasopharyngeal carcinoma (NPC) is urgent. Therefore, we performed this systematic review of the literature with meta-analysis to clarify and explore the associate expression of nm23-H1 with prognosis of NPC patients.
Literature research in Cochrane Library, PubMed, and EMBASE was performed up to July 2016. Eligible case-control studies of associate expression of nm23-H1 with prognosis of NPC patients were included.
Nine studies met our inclusion criteria and were finally included for the analysis, involving 861 participants. Our meta-analysis revealed that the low expression of nm23-H1 in NPC was: RR = 2.13, 95% CI 1.15-3.95 and R = 2.56, 95% CI 2.03-3.22; and poorer overall survival (OS) rate was 3-year OS rate: RR: 0.55; 95% CI: 0.45-0.67 and 5-year OS rate: RR: 0.60; 95% CI: 0.52-0.69. Furthermore, the statistical significance was constant irrespective of different NPC subtypes.
The low expression of nm23-H1 is associated with poorer prognosis in patients with NPC, suggesting that it is a prognostic factor and potential biomarker for survival in NPC.
开发一种新的可靠预后标志物以预测鼻咽癌（NPC）患者的预后并为其提供更好、更合适的治疗迫在眉睫。因此，我们进行了这项带有荟萃分析的文献系统评价，以阐明和探索nm23-H1与NPC患者预后的相关性表达。
截至2016年7月，在Cochrane图书馆、PubMed和EMBASE数据库中进行文献检索。纳入符合条件的关于nm23-H1与NPC患者预后相关性表达的病例对照研究。
9项研究符合我们的纳入标准，最终纳入分析，涉及861名参与者。我们的荟萃分析显示，NPC中nm23-H1低表达为：RR = 2.13，95%CI 1.15 - 3.95；R = 2.56，95%CI 2.03 - 3.22；总体生存率（OS）较差的是3年OS率：RR：0.55；95%CI：0.45 - 0.67，5年OS率：RR：0.60；95%CI：0.52 - 0.69。此外，无论NPC的不同亚型如何，统计学意义均保持不变。
nm23-H1低表达与NPC患者较差的预后相关，表明它是NPC患者生存的一个预后因素和潜在生物标志物。
